Sajni Josson, PhD

Research Scientist I

Sajni Josson, PhD is a research scientist in the Uro-Oncology Department of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai.
Dr. Josson's research focuses on the role of a pleotropic signaling protein, β2-microglobulin (β2M), in prostate cancer bone metastasis. Bone metastasis is the major cause of death in prostate cancer patients. β2M is a signaling molecule involved in epithelial to mesenchymal transition, osteomimicry and regulating iron homeostasis. It is also involved in the vicious cycle of tumor-stromal microenvironment interaction. Current studies by Dr Josson are focused on characterizing the β2M signaling pathway involving regulatory miRNA and redox proteins in this metastatic switch.

Dr. Josson's studies have been published in several peer-reviewed publications including Cancer Research, Oncogene and Prostate. She is a member of the Society for Basic Urologic Research and Society of Free Radical Biology and Medicine.

Dr. Josson earned her bachelor's degree from Wilson College, Mumbai, a master's in Applied Medicine from St. Xavier's College, Mumbai and a doctorate in Toxicology from the Graduate Center for Toxicology, University of Kentucky. She then completed a postdoctoral fellowship in prostate cancer metastasis and radiation oncology at the Emory University School of Medicine.
 

CV: Sajni Josson, PhD  

Selected Recent Publications

1) Josson S., Matsuoka Y., Chung LWK., Zhau HE., and Wang R., "Tumor stoma co-evolution in prostate cancer progression and metastasis" Seminars in Cell and Developmental Biology, Dec. 3, Epub. (2009)

2) Xu* Y., Josson* S., Fang F., Oberley TD., Clair DK., Wan SX., Sun Y., Bakthavatchalu V., Muthuswamy A.,and Clair WH. "RelB Enhances Prostate Cancer Growth: Implications for the Role of the NF-kappa B Alternative Pathway in Tumorigenicity", Cancer Res Apr 15; 69(8):3267-71. (2009) * Co-first author.

3) Josson S., Sung S-Y., Lao K., Chung LWK., and Johnstone PAS., "Radiation modulation of microRNA in prostate cancer cell lines" Prostate, Nov 1;68(15):1599-606. (2008)

4) Xu Y., Fang F., Clair DK., Sompol P., Josson S., and Clair WH., "SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation", Mol Cancer Ther, Aug;7(8):2367-76. (2008)

5) Xu Y., Fang F., Clair DK., Josson S., Sompol P., Spasojevic I., and Clair WH., "Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1{alpha},25-dihydroxyvitamin D3 in prostate cancer cells", Mol Cancer Ther, Jul; 6(7):2048-56. (2007)